Phase I/II Study of Lutathera in Patients with Recurrent And/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications CNS cancer; Glioma; Meningioma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Nov 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Nov 2027.
- 16 Jan 2023 Planned End Date changed from 20 Dec 2026 to 1 Nov 2027.
- 16 Jan 2023 Planned primary completion date changed from 20 Dec 2025 to 1 Nov 2025.